中國人壽(02628.HK)被SEC初步認定為「外國公司問責法案」發行人
中國人壽(02628.HK)公布,公司向SEC(美國證券交易委員會)提交2021年止年度的20-F表格年度報告之後,本月4日,被SEC初步認定為《外國公司問責法案》項下的委員會認定發行人,表明SEC認為公司使用了一家目前無法由美國公眾公司會計監督委員會(PCAOB)檢查的註冊會計師事務所對2021年止年度的財務報表出具審計意見。
根據問責法案,如果一家公司連續三年被SEC認定為問責法案項下的委員會認定發行人,SEC應禁止該公司的股票或美國存託股票在美國的全國性證券交易所或場外交易市場交易。公司將繼續嚴格遵守中美相關法律法規並持續關注市場動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.